The role of prostate specific antigen measurement in the detection and management of prostate cancer

Endocrine-Related Cancer

Volumn 7, Issue 1, 2000, Pages 37-51

  Nash, A F ^a   Melezinek, I ^a  

^a ASTRAZENECA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

FINASTERIDE; PROSTATE SPECIFIC ANTIGEN;

AGE; ANTIGEN DETECTION; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CANCER SCREENING; CLINICAL EXAMINATION; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; HUMAN; PROSTATE CARCINOMA; PROSTATECTOMY; REVIEW;

EID: 0034067029     PISSN: 13510088     EISSN: None     Source Type: Journal    
DOI: 10.1677/erc.0.0070037     Document Type: Review

References (145)

1. Agha AH, Schecter E, Roy JB & Culkin DJ 1996 Prostate specific antigen is metabolised in the liver. Journal of Urology 155 1332-1335.
2. Akakura K, Bruchovsky N, Goldenberg SL, Rennie PS, Buckley AR & Sullivan D 1993 Effects of intermittent androgen suppression on androgen-dependent tumours: apoptosis and serum prostate-specific antigen. Cancer 71 2782-2790.
3. Alexander FE & Prescott RJ 1999 Reply to Labrie et al. - Letter. Prostate 40 135-136.
4. Altwein J & Schmidt A 1999 Bicalutamide (Casodex) and castration in advanced prostate cancer (aPC): prognostic relevance of PSA levels and rate of change. European Urology 35 (Suppl 2) Abstract 55.
5. Andriole GL, Guess HA, Epstein JI, Wise H, Kadmon D, Crawford ED, Hudson P, Jackson CL, Romas NA, Patterson L, Cook TJ & Waldstreicher J 1998 Treatment with finasteride preserves usefulness of prostate-specific antigen in the detection of prostate cancer: results of a randomised, double blind, placebo-controlled clinical trial. PLESS Study Group. Proscar long term efficacy and safety study. Urology 52 195-201.
6. Bales GT & Chodak GW 1996 A controlled trial of bicalutamide versus castration in patients with advanced prostate cancer. Urology 47 (Suppl 1A) 38-43.
7. Bangma CH, Kranse R, Blijenberg BG & Schröder FH 1995 The value of screening tests in the detection of prostate cancer. Part 2: retrospective analysis of free/total prostate-specific analysis ratio, age-specific reference ranges and PSA density. Urology 46 779-784.
8. Bazinet M, Meshref AW, Trudel C, Aronson S, Peloquin F, Nachabe M, Begin LR & Elhilali M 1994 Prospective evaluation of prostate specific antigen density and systematic biopsies for early detection of prostatic carcinoma. Urology 43 44-51.
9. Benson MC, Whang IS, Pantuck A, Ring K, Kaplan SA, Olsson CA & Cooner WH 1992 Prostate specific antigen density: a means of distinguishing benign prostatic hypertrophy and prostate cancer. Journal of Urology 147 815-816.
10. Blackledge GRP & Lowery K 1994 Role of prostate-specific antigen as a predictor of outcome in prostate cancer. Prostate (Suppl) 55 34-38.
11. Boer R & Schroder FH 1999 Quebec randomised controlled trial on prostate cancer screening shows no evidence for mortality reduction - Letter. Prostate 40 130-131.
12. Boring C, Squires T & Montgomery S 1994 Cancer statistics. A Cancer Journal for Clinicians 44 7-26.
13. Boyle P 1994 Prostate cancer 2000: evolution of an epidemic of unknown origin. In Prostate Cancer 2000, pp 5-11. Ed L Denis. Heidelberg: Springer-Verlag.
14. Brawer MK, Aramburu EAG, Chen GL, Preston SD & Ellis WJ 1993 The inability of prostate specific antigen index to enhance the predictive value of prostate specific antigen in the diagnosis of prostatic carcinoma. Journal of Urology 150 369-373.
15. Carter HB, Pearson JD, Metter EJ, Brant LJ, Chan DW, Andres R, Fozard JL & Walsh PC 1992 Longitudinal evaluation of prostate specific antigen levels in men with and without prostate disease. Journal of the American Medical Association 267 2215-2220.
16. Catalona WJ & Smith D 1994 Five year tumour recurrence rates after anatomical radical retropubic prostatectomy for prostate cancer. Journal of Urology 152 1837-1842.
17. Catalona WJ, Smith DS, Ratliff TL, Dodds KM, Coplen DE, Yuan JJ, Petros JA & Andriole GL 1991 Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. New England Journal of Medicine 324 1156-1161.
18. Catalona WJ, Richie JP, Ahmann FR, M' Hudson MA, Scardino PT, Flanigan RC, deKemion JB, Ratliff TL, Kavoussi LR, Dalkin BL, Waters WB, MacFarlane MT & Southwick PC 1994a Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicentre clinical trial of 6630 men. Journal of Urology 151 1283-1290.
19. Catalona WJ, Richie JP, deKernion JB, Ahmann FR, Ratliff TL, Dalkin BL, Kavoussi LR, MacFarlane MT & Southwick PC 1994b Comparison of prostate specific antigen concentration versus prostate specific antigen density in the early detection of prostate cancer, receiver operating characteristic curves. Journal of Urology 152 2031-2036.
20. Catalona WJ, Hudson MA, Scardino PT, Richie JP, Ashmann FR, Flanigan RC, de Kernion JB, Ratliff TL, Kavoussi LR & Dalkin BL 1994c Selection of optimal prostate specific antigen cutoffs for early detection of prostate cancer: receiver operating characteristic curves. Journal of Urology 152 2037-2042.
21. Catalona WJ, Smith DS, Wolfert R, Wang TJ, Rittenhouse H, Ratliff TL & Nadler RB 1995 Evaluation of percentage of free serum prostate-specific antigen to improve specificity of prostate cancer screening. Journal of the American Medical Association 274 1214-1220.
22. Chan DW, Bruzek DJ, Oesterling JE, Rock RC & Walsh PC 1987 Prostate specific antigen as a marker for prostatic cancer: a monoclonal and polyclonal immunoassay compared. Clinical Chemistry 33 1916-1920.
23. Chen YT, Luderer AA, Thiel RP, Carlson G, Cuny CL & Soriano TF 1996 Using proportions of free to total prostate specific antigen, age and total prostate specific antigen to predict the probability of prostate cancer. Urology 47 518-528.
24. Chodak G, Sharifif R, Chasms B, Block NL, Marcella E & Kenneally GT 1995 Single agent therapy with bicalutamide: a comparison with medical or surgical castration in the treatment of advanced prostate carcinoma. Urology 46 849-855.
25. Christensson A, Laurell CB & Lilja H 1990 Enzymatic activity of prostatic specific antigen and its reactions with extracellular serine protease inhibitors. European Journal of Biochemistry 194 755-763.
26. Christensson A, Bjork T, Nilsson O, Dahlen U, Matikainen M, Cockett ATK, Abrahamsson PA & Lilja H 1993 Serum prostate specific antigen complexed to alpha-1 antichymotrypsin as an indicator of prostate cancer. Journal of Urology 150 100-105.
27. Collins GN, Lee RJ, McKelvie GB, Rogers CAN & Hehir M 1993 Relationship between prostate specific antigen, prostate volume and age in the benign prostate. British Journal of Urology 71 445-450.
28. Corey E, Arfman E, Oswin M, Melchior S, Tindall D, Young C, Ellis W & Vessella R 1997 Detection of circulating prostate cells by reverse transcriptase-polymerase chain reaction of human glandular kallikrein (hK2) and prostate-specific antigen (PSA) messages. Urology 50 184-188.
29. Crawford ED 1994 Report on the 1993 Prostate Cancer Awareness Week. Read at Annual Meeting of the American Urological Association, San Francisco, California, 14-19 May 1994.
30. Crawford ED, Eisenberger MA, McLeod DG, Spaulding JT, Benson R, Dorr A, Blumenstein B, Davis MA & Goodwin PJ 1989 A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. New England Journal of Medicine 321 419-424.
31. Creasy T, Lesna M, Rundle D, Bramble J & Morley R 1997 Central gland PSA density - a more sensitive tool for the diagnosis of carcinoma of the prostate. Journal of Urology 157 55 Abstract 209.
32. 125 implant followed by external beam radiation. Cancer 75 2383-2391.
33. Critz FA, Levinson AK, Williams WH, Holladay DA & Holladay CT 1997 The PSA nadir that indicates potential cure after radiotherapy for prostate cancer. Urology 49 322-326.
34. Crook JM, Bahadur YA, Bociek RG, Perry GA, Robertson SJ & Esche BA 1997 Radiotherapy for localised prostate cancer. Cancer 79 328-336.
35. Culig Z, Hobisch A, Hittmair A, Cronauer MV, Radmayr C, Bartsch G & Clocker H 1997 Androgen receptor gene mutations in prostate cancer. Drugs and Aging 10 50-57.
36. Dalkin BL, Ahmann FR & Kopp JB 1993 Prostate specific antigen levels in men older than 50 years without clinical evidence of prostatic carcinoma. Journal of Urology 150 1837-1839.
37. Djavan B, Zlotta AR, Byttebier G, Shariat S, Omar M, Schulman CC & Marberger M 1998 Prostate specific antigen density of the transition zone for early detection of prostate cancer. Journal of Urology 160 411-418.
38. Debruyne FMJ, de Gery A, Huchee M & Godfroid N 1996 Maximum androgen blockade with nilutamide combined with orchidectomy in advanced prostate cancer: an updated meta-analysis of 7 randomised placebo-controlled trials (1191 patients). European Urology 30 (Suppl 2) 264 Abstract 990.
39. Denis LJ, Whelan P, Carneiro de Moura JL, Newling D, Bono A, Depauw M & Sylvester R 1993 Goserelin acetate and flutamide versus bilateral orchidectomy: a phase 3 EORTC trial [30853]. Urology 42 119-129.
40. Eisenberger MA, Blumenstein BA, Crawford ED, Miller G, McLeod DG, Lochrer PJ, Wilding G, Sears K, Cukin DJ, Thompson IM Jr, Bueschen AJ & Lowe BA 1998 Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. New England Journal of Medicine 339 1036-1042.
41. Ellis WJ, Vessela RL, Noteboom JL, Lange PH, Wolfert RL & Rittenhouse HG 1997 Early detection of recurrent prostate cancer with an ultrasensitive chemiluminescent prostate specific antigen assay. Urology 50 573-579.
42. Farkas A, Schneider D, Perroti M, Cummings KB & Ward WS 1998 National trends in the epidemiology of prostate cancer, 1973 to 1994: evidence for the effectiveness of prostate-specific antigen screening. Urology 52 444-449.
43. Frazier HA, Humphrey PA, Burchette JL & Paulson DF 1992 Immunoreactive prostatic specific antigen in male periurethral glands. Journal of Urology 147 246-248.
44. Gao CL, Dean RC, Pinto A, Mooneyhan R, Connelly RR, McLeod DG, Srivastava S & Moul JW 1999 Detection of circulating prostate specific antigen expressing prostatic cells in the bone marrow of radical prostatectomy patients by sensitive reverse transcriptase-polymerase chain reaction. Journal of Urology 161 1070-1076.
45. Ghossein R, Scher H, Gerald W, Kelly WK, Curley T, Amsterdam A, Zhang Z & Rosai J 1995 Detection of circulating tumour cells in patients with localised and metastatic prostatic carcinoma: clinical implications. Journal of Clinical Oncology 13 1195-1200.
46. Ghossein RA, Rosai J́, Scher HI, Seiden MV, Zhang ZF, Sun M, Chang G, Berlane K, Krithivas K & Kantoff PW 1997 Prognostic significance of detection of prostate specific antigen transcripts in the peripheral blood of patients with metastatic androgen-independent prostatic carcinoma. Urology 50 100-105.
47. Gleave M, Bruchovsky N, Bowden M, Goldenberg SL & Sullivan D 1994 Intermittent androgen suppression prolongs time to androgen-independent progression in the LNCaP prostate tumour model. Journal of Urology 151 457A.
48. Gohagan JK, Prorok PC, Kramer BS & Cornett JE 1994 Prostate cancer screening in the Prostate, Lung, Colorectal and Ovarian screening trial of the National Cancer Institute. Journal of Urology 152 1905-1909.
49. Goldenberg LS, Bruchovsky N, Gleave M, Sullivan LD & Akakura K 1995 Intermittent androgen suppression in the treatment of prostate cancer: a preliminary report. Urology 45 839-844.
50. Gormley GJ, Stoner E, Bruskewitz RC, Imperato-McGinley J, Walsh PC, McConnell JD, Andriole GL, Geller J & Bracken BR for the Finasteride Study Group 1992 The effect of finasteride in men with benign prostatic hyperplasia. New England Journal of Medicine 327 1185-1191.
51. Hammerer PG, McNeal JE & Stamey TA 1995 Correlation between serum prostate specific antigen levels and the volume of the individual glandular zones of the human prostate. Journal of Urology 153 111-114.
52. Hanks GE, Hanlon A, Schultheiss T, Corn B, Shipley WV & Lee WR 1994 Early prostate cancer: the national results of radiation treatment from the patterns of care and radiation therapy oncology group studies with prospects for improvement with conformal radiation and adjuvant androgen deprivation. Journal of Urology 152 1775-1780.
53. Hara M, Koyanagi Y, Inoue T & Fukuyama T 1971 Some physico-chemical characteristics of gamma seminoprotein, an antigenic component specific for human seminal plasma. Nippon Hoigaku Zasshi 25 322-324.
54. Herschman JD, Smith DS & Catalona WJ 1997 Effect of ejaculation on serum total and free prostate specific antigen concentrations. Urology 50 239-243.
55. Hoeksema MJ & Law C 1996 Cancer mortality rates fall: a turning point for the nation. Journal of the National Cancer Institute 88 1706-1707.
56. Horninger W, Reissigl A, Klocker H, Holtl L, Fink K & Bartsch G 1997 Improvement of early detection of prostate cancer by using PSA-transitional zone density (PSA-TZ density) and percent free PSA in addition to total PSA levels. Journal of Urology 157 116 Abstract 454.
57. Humphrey PA, Keetch DW, Smith DS, Shepherd DL & Catalona W 1996 Prospective characterisation of pathological features of prostatic carcinomas detected via serum prostate specific antigen based screening. Journal of Urology 155 816-820.
58. Ignatoff JM, Oefelein MG, Watkin W, Chmiel JS & Kaul KL 1997 Prostate specific antigen reverse transcriptase polymerase chain reaction assay in preoperative staging of prostate cancer. Journal of Urology 158 1870-1875.
59. Iversen P, Tyrell CJ, Kaisary AV, Anderson JB, Baert L, Tammela T, Chamberlain M, Carroll K, Gotting-Smith K & Blackledge GRP 1998 Casodex (bicalutamide) 150 mg monotherapy compared with castration in patients with previously untreated non-metastatic prostate cancer: results from two multicentre randomised trials at a median follow-up of 4 years. Urology 51 389-396.
60. Janknegt RA, Maastricht NL, Crawford ED & Denver CO 1996 Long term efficacy and safety of maximal androgen blockade (MAB) with nilutamide (Ananadron) and castration in stage D2 prostate cancer. European Urology 30 (Suppl 2) 264 Abstract 991.
61. Jung K, Meyer A, Lein M, Rudolph B, Schnorr D & Loening S 1998 Ratio of free to total prostate specific antigen in serum cannot distinguish patients with prostate cancer from those with chronic inflammation of the prostate. Journal of Urology 159 1595-1598.
62. Kadmon D, Weinberg A, Williams RH, Pavlik VN, Copper P & Migliore PJ 1996 Pitfalls in interpreting prostate specific antigen velocity. Journal of Urology 155 1655-1657.
63. Kaisary AV 1994 Current clinical studies with a new non-steroidal antiandrogen, Casodex. Prostate (Suppl) 5 27-33.
64. Katz AE, Olsson CA, Raffo AJ, Cama C, Perlmann H, Seaman E, O'Toole KM, McMahon D, Benson MC & Buttyan R 1994 Molecular staging of prostate cancer with the use of an enhanced reverse transcriptase-PCR assay. Urology 45 765-775.
65. Katz AE, deVries GM, Olsson CA, Benson MC, Swanton PI, Keguchi EF & Buttyan R 1996 Molecular staging of genito-urinary malignancies. Urology 47 948-958.
66. Kawakami M, Okaneya T, Kenichi F, Nishizawa O & Katsuyama T 1997 Detection of prostate cancer cells circulating in peripheral blood by reverse transcription-PCR for hKL2. Cancer Research 57 4167-4170.
67. Keetch DW, McMurtry JM, Smith DS, Andriole GL & Catalona WJ 1996 Prostate specific antigen density versus prostate specific antigen slope as predictors of prostate cancer in men with initially negative prostatic biopsies. Journal of Urology 156 428-431.
68. Kelly WK, Scher HI, Mazumdar M, Vlamis V, Schwartz M & Fossa SD 1993 Prostate specific antigen as a measure of disease outcome in metastatic hormone-refractory prostate cancer. Journal of Clinical Oncology 11 607-615.
69. Klotz LH & Newman T 1996 Does maximal androgen blockade (MAB) improve survival? A critical appraisal of the evidence. Canadian Journal of Urology 3 246-250.
70. Kolvenbag GJCM, Blackledge GRP & Gotting-Smith K 1998 Bicalutamide (Casodex) in the treatment of prostate cancer: history of clinical development. Prostate 34 61-72.
71. Kurita Y, Ushiyama T, Suzuki K, Fujita K & Kawabe K 1996 PSA value adjusted for the transition zone volume in the diagnosis of prostate cancer. International Journal of Urology 3 367-372.
72. Labrie F & Candas B 1999a Various statistical analyses indicate a marked reduction of prostate cancer death in the Quebec trial -Letter. Prostate 40 132-134.
73. Labrie F & Candas B 1999b The Quebec study shows a 69% decrease in prostate cancer death - Letter. Prostate 40 137.
74. Labrie F, Candas B, Dupont A, Cusan L, Gomez J-L, Suburu RE, Diamond P, Levesque J & Bealanger A 1999 Screening decreases prostate cancer death: first analysis of the 1988 Quebec prospective randomised controlled trial. Prostate 38 83-91.
75. Lee WR, Hanlon AL & Hanks GE 1996 Prostate specific antigen nadir following external beam radiotherapy for clinically localised prostate cancer: the relationship between nadir level and disease free survival. Journal of Urology 156 450-453.
76. Leo ME, Bilhartz DL, Bergstralh EJ & Oesterling JE 1991 Prostate specific antigen in hormonally treated stage D2 prostate cancer: is it always an accurate indicator of disease status? Journal of Urology 145 802-806.
77. Lepor H, Wang B & Shapiro E 1994 Relationship between prostatic epithelial volume and serum prostate-specific antigen levels. Urology 44 199-205.
78. Lilja H 1985 Kallikrein-like serine protease in prostatic fluid cleaves the predominant seminal vesicle protein. Journal of Clinical Investigation 76 1899-1903.
79. Lilja H 1993 Significance of different molecular forms of serum PSA: the free, non-complexed form of PSA versus that complexed to alpha-1-antichymotrypsin. Urology Clinics of North America 20 681-686.
80. Lilja H, Christennson A, Dahlen U, Matikainen MT, Nilsson O, Petterson K & Lovgren T 1991 Prostate specific antigen in serum occurs predominantly in complex with alpha-1-antichymotrypsin. Clinical Chemistry 37 1618-1625.
81. Lu S, Tsai SY & Tsai MJ 1997 Regulation of androgen-dependent prostatic cancer cell growth: androgen regulation of CDK2, CDK4 and CK1 p16 genes. Cancer Research 57 4511-4516.
82. Luderer AA, Chen YT, Soriano TF, Kramp WJ, Carlson G, Cuny C, Sharp T, Smith W, Petteway J, Brawer MK & Thiel R 1995 Measurement of the proportion of free to total prostate specific antigen improves diagnostic performance of prostate specific antigen in the diagnostic grey zone of total prostate specific antigen. Urology 46 187-194.
83. Lundwall A & Lilja H 1987 Molecular cloning of human prostate specific antigen cDNA. FEBS Letters 214 317.
84. McCormack RT, Rittenhouse HG, Finlay JA, Sokoloff RL, Wang TJ, Wolfert RL, Lilja H & Oesterling JE 1995 Molecular forms of prostatic specific antigen and the kallikrein gene family: a new era. Urology 45 729-744.
85. Melchior SW, Corey E, Ellis WJ, Ross AA, Layton TJ, Oswin MM, Lange PH & Vessella RL 1997 Early tumour cell dissemination in patients with clinically localised carcinoma of the prostate. Clinical Cancer Research 3 249-256.
86. Messing E, Manola J, Wilding G, Sarosdy M, Crawford D & Trump D 1999 Immediate hormonal therapy vs observation for node positive prostate cancer following radical prostatectomy and pelvic lymphadenectomy: a randomised phase III Eastern Cooperative Oncology Group/Inter Group Trial. Journal of Urology 161 (Suppl 175) 4 Abstract 673.
87. Mettlin CJ, Murphy GP & Menck HR 1997 Changes in patterns of prostate cancer care in the United States: results of American College of Surgeons Commission on Cancer studies 1974-1993. Prostate 32 221-226.
88. Miller JL, Ahman F, Drach G, Emerson SS & Bottacini MR 1992 The clinical usefulness of serum prostate specific antigen after hormonal therapy of metastatic prostate cancer. Journal of Urology 147 956-961.
89. Moyad R, Song JT & Belville WD 1994 The impact of ejaculation on serum prostate specific antigen (PSA) levels in men over the age of 40. Journal of Urology 151 (Suppl) Abstract 689.
90. Netto NR, Apuzzo F, deAndrade E, Srulzon GB, Cortado PL & Lima ML 1996 The effects of ejaculation on serum prostate specific antigen. Journal of Urology 155 1329-1331.
91. Oesterling JE, Jacobsen SJ, Chute CG, Guess HA, Girman CJ, Panser LA & Lieber MM 1993 Serum prostate specific antigen in a community based population of healthy men: establishment of age-specific reference ranges. Journal of the American Medical Association 270 860-864.
92. Oesterling JE, Jacobsen SJ, Klee GG, Petterson K, Piironen T, Abrahamsson PA, Stenman UH, Dowell B, Lovgren T & Lilja H 1995 Free, complexed and total prostate specific antigen: the establishment of appropriate reference ranges for their concentrations and ratios. Journal of Urology 154 1090-1095.
93. Oesterling JE, Roy J, Agha A, Shawn T, Krarup T, Johansen T, Lagerkuist M, Gormley G, Bach M & Waldstreicher J 1997 Biologic variability of prostate-specific antigen and its usefulness as a marker for prostate cancer: effects of finasteride. The Finasteride PSA Study Group. Urology 50 13-18.
94. Olsson CA, deVries GM, Raffo AJ, Benson MC, O'Toole K, Cao Y, Buttyan RE & Katz AE 1996 Preoperative reverse transcriptase-polymerase chain reaction for prostate specific antigen predicts treatment failure following radical prostatectomy. Journal of Urology 155 1557-1562.
95. Papsidero LD, Wang MC, Valenzuela LA, Murphy GP & Chu TM 1980 A prostate antigen in sera of prostatic cancer patients. Cancer Research 40 2428-2432.
96. Partin AW, Pound CR, Clemens JQ, Epstein JI & Walsh PC 1993 Serum PSA after anatomic radical prostatectomy. Urology Clinics of North America 20 713-725.
97. Partin A, Catalona WJ, Southwick PC, Subong EN, Gasior GH & Chan DW 1996a Analysis of percent free prostate specific antigen PSA for prostate cancer detection: influence of total PSA, prostate volume and age. Urology (Suppl) 48 55-61.
98. Partin AW, Criley SR, Subong EN, Zincke H, Walsh PC & Oesterling JE 1996b Standard versus age-specific reference ranges among men with clinically localised prostate cancer: a pathological analysis. Journal of Urology 155 1336-1339.
99. Pettersson K, Piironen T, Seppala M, Liukkonen L, Christensson A, Matikainen MT, Suonpaa M, Lovgren T & Lilja H 1995 Free and complexed prostate specific antigen (PSA): in vitro stability, epitope map and development of immunofluorimetric assays for specific and sensitive detection of free PSA and PSA-alpha-1 antichymotrypsin complex. Clinical Chemistry 41 1480-1488.
100. Pienta KJ, Redman B, Hussein M, Cummings G, Esper PS, Appel C & Flaherty LE 1994 Phase II evaluation of oral estramustine and oral etoposide in hormone refractory adenocarcinoma of the prostate. Journal of Clinical Oncology 12 2005-2012.
101. Prestigiacomo AF, Lilja H, Petterson K, Wolfert RL & Stamey TA 1996 A comparison of the free fraction of serum prostate specific antigen in men with benign and cancerous prostates: the best case scenario. Journal of Urology 156 350-356.
102. Preston D, Bauer J, Connelly R, Sawyer T, Halligan J, Leifer E, Mcleod D & Moul J 1999 Prostate-specific antigen to predict outcome of external beam radiation for prostate cancer: Walter Reed Army Medical Center Experience 1988-1995. Urology 53 131-138.
103. Prostate Cancer Trialists' Collaborative Group 1995 Maximal androgen blockade in advanced prostate cancer: an overview of 22 randomised trials with 3283 deaths in 5710 patients. Lancet 346 265-269.
104. Pruthi RS, Johnstone I, I-Ping Tu & Stamey TA 1997 Prostate specific antigen doubling times in patients who have failed radical prostatectomy: correlation with histologic characteristics of the primary cancer. Urology 49 737-742.
105. Rosenzweig KE, Morgan WR, Lytton B & Peschel RE 1995 Prostate specific antigen following radiotherapy for local prostate cancer. Journal of Urology 153 1561-1564.
106. Scardino PT, Weaver R & Hudson MA 1992 Early detection of prostate cancer. Human Pathology 23 211-222.
107. Schaller J, Akiyama K, Tsuda R, Hara M, Marti T & Rickliu E 1987 Isolation, characterisation and amino acid sequence of gamma seminoprotein, a glycoprotein from human seminal plasma. European Journal of Biochemistry 170 111-120.
108. Schellhammer P & Wright G Jr 1993 Biomolecular and clinical characteristics of PSA and other candidate prostate tumour markers. Urology Clinics of North America 20 597-606.
109. Schellhammer P, El-Mahadi AM, Wright GL, Kolm P & Ragle R 1993 Prostate specific antigen to determine progression free survival after radiation therapy for localised carcinoma of prostate. Urology 42 13-20.
110. Schellhammer PF, Sharifi R, Block NL, Soloway MS, Venner PM, Patterson AL, Sarosdy MF, Vogelzang NJ, Schellenger JJ & Kolvenbag GJ 1997 Clinical benefits of bicalutamide compared with flutamide in combined androgen blockade for patients with advanced prostatic carcinoma: final report of a double-blind, randomised, multicenter trial. Casodex Combination Study Group. Urology 50 330-336.
111. Scher HI, Curley T, Geller N, Engstrom C, Dershaw DD, Lin SY, Fitzpatrick K, Nisselbaum J, Schwartz M, Bezerdjian L & Eisenberger M 1990 Trimetrexate in prostatic cancer: preliminary observations on the use of prostate specific antigen and acid phosphatase as a marker in measurable hormone-refractory disease. Journal of Clinical Oncology 8 1830-1838.
112. Schröder FH, Kranse R, Rietbergen J, Hoedemaeker R, Kirkels W & members of the ERSPC, Section Rotterdam 1999 The European Randomised Study of Screening for Prostate Cancer (ERSPC): an update. European Urology 35 539-543.
113. Sella A, Kilbourn R, Amato R, Bui C, Zukiwski AA, Ellerhorst J & Logothetis CJ 1994 Phase II study of ketoconazole combined with weekly doxorubicin in patients with androgen-independent prostate cancer. Journal of Clinical Oncology 12 683-688.
114. Sensabaugh GH 1978 Isolation and characterisation of a semen-specific protein from human seminal plasma: a potential new marker for serum identification. Journal of Forensic Science 23 106-115.
115. Smith DS & Catalona WJ 1994 Rate of change in serum prostate specific antigen levels as a method for prostate cancer detection. Journal of Urology 152 1163-1167.
116. Sokoloff MH, Tso C, Kaboo R, Nelson S, Ko J, Dorey F, Figlin RA, Pang S, deKemion J & Belldegrun A 1996 Quantitative polymerase chain reaction does not improve preoperative prostate cancer staging: a clinicopathological molecular analysis of 121 patients. Journal of Urology 156 1560-1566.
117. Stamey TA, Yang N, Hay AR, McNeal JE, Freiha FS & Redwine E 1987 Prostate specific antigen as a serum marker for adenocarcinoma of the prostate. New England Journal of Medicine 317 909-916.
118. Stamey TA, Kabalin JN, Ferrari M & Yang N 1989 Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. IV. Anti-androgen treated patients. Journal of Urology 141 1088-1090.
119. Stamey TA, Graves HC, Wehener N, Ferrari M & Freiha FS 1993 Early detection of residual prostate cancer after radical prostatectomy by an ultrasensitive assay for prostate specific antigen. Journal of Urology 149 787-792.
120. Stein A, deKemion JB, Smith RB, Dorey F & Patel H 1992 Prostate specific antigen levels after radical prostatectomy in patients with organ-confined and locally extensive prostate cancer. Journal of Urology 147 942-946.
121. Stenman UH, Leinonen J, Alfthan H, Rannikko S, Tuhkanen K & Alfthan O 1991 A complex between prostate specific antigen and alpha-1-antichymotrypsin is the major form of prostate specific antigen in serum of patients with prostatic cancer. Assay of the complex improves clinical sensitivity for cancer. Cancer Research 51 222-226.
122. Stock RG, Stone NN & DeWyngaert JK, Laragnini P & Unger PD 1996 Prostate specific antigen findings and biopsy results following interactive ultrasound guided transperineal brachytherapy for early stage prostate carcinoma. Cancer 77 2386-2392.
123. Takayama TK, Vessella RL, Brawer MK, Noteboom J & Lange PH 1993 The enhanced detection of persistent disease after prostatectomy with a new PSA immunoassay. Journal of Urology 150 374-378.
124. Takayama TK, Vessela RL, Brawer MK, True LD, Noteboom J & Lange PH 1994 Urinary PSA levels after radical prostatectomy. Journal of Urology 151 82-87.
125. Tchetgen MB, Song JT, Strawderman M, Jacobsen SJ & Oesterling JE 1996 Ejaculation increases the serum prostate specific antigen concentration. Urology 47 511-516.
126. Thalmann GN, Sikes RA, Chang SM, Johnston DA, von Eschenbach AC & Chung LW 1996 Suramin-induced decrease in prostate-specific antigen expression with no effect on tumour growth in the LNCaP model of human prostate cancer. Journal of the National Cancer Institute 88 794-801.
127. Trapasso JG, deKernion JB, Smith RB & Dorey F 1994 The incidence and significance of detectable levels of serum prostate specific antigen after radical prostatectomy. Journal of Urology 152 1821-1825.
128. Tunn UW 1996 Intermittent endocrine therapy of prostate cancer. European Journal of Urology (Suppl) 1 22-25.
129. Tyrell CJ, Kaisary AV, Iversen P, Andersond JB, Baerte L, Tammela T, Chamberlain M, Webster A & Blackledge G 1998 A randomised comparison of Casodex (bicalutamide) 150 mg monotherapy versus castration in the treatment of metastatic and locally advanced prostate cancer. European Urology 33 447-456.
130. Van Cangh PJ, De Nayer P, Sauvage P, Tombal B, Elsen M, Lorge F, Opsomer R & Wese FX 1996 Free:total prostate specific antigen (PSA) ratio is superior to total PSA in differentiating benign prostate hypertrophy from prostate cancer. The Prostate (Suppl) 7 30-34.
131. Visakorpi T, Hyytinen E, Koivosto P, Tanner M, Keinanen R, Palmberg C, Palotie A, Tammela T, Isola J & Kallioniemi O 1995 In vivo amplification of the androgen receptor gene and progression of human cancer. Nature Genetics 9 401-406.
132. Von Eschenbach A, Ho R, Murphy GP, Cunningham M & Lins N 1997 American Cancer Society guidelines for the early detection of prostate cancer: update, June 10 1997. Cancer 80 1805-1807.
133. Wallner K, Roy J & Harrison L 1996 Tumor control and morbidity following transperineal iodine125 implantation for stage T1/T2 prostatic carcinoma. Journal of Clinical Oncology 14 449-453.
134. Walls R, Thibault A, Lei L, Wood C, Kozlowski J, Figg W, Sampson M, Elin R & Samid D 1996 The differentiating agent, phenylacetate, increases prostatic-specific antigen production by prostate cancer cells. Prostate 29 177-182.
135. Wang MC, Valenzuela LA, Murphy GP & Chu TM 1979 Purification of a human prostate specific antigen. Investigative Urology 17 159-163.
136. Watt KWK, Lee PJ, M'Timkulu T, Chan WP & Loor R 1986 Human prostate specific antigen; structural and functional similarity with serine proteases. Proceedings of the National Academy of Sciences of the USA 83 3166-3170.
137. Wingo P, Landis S & Ries L 1997 An adjustment to the 1997 estimate for new prostate cancer cases. A Cancer Journal for Clinicians 47 239-242.
138. Wirth M, Frohmuller H, Marx F, Bolten M & Theiss 1997 Randomised multicentre trial on adjuvant flutamide therapy in locally advanced prostate cancer after radical surgery - interim analysis of treatment effect and prognostic factors. British Journal of Urology 80 (Suppl 2) Abstract 1033.
139. Wood D, Banks E, Humphreys S, McRoberts J & Rangnekar V 1994 Identification of bone marrow micrometastases in patients with prostate cancer. Cancer 74 2533-2540.
140. Woodrum DL, Brawer MK, Partin AW, Catalona WJ & Southwick PC 1998 Interpretation of free prostate specific antigen clinical research studies for the detection of prostate cancer. Journal of Urology 159 5-12.
141. Yu H, Diamandis EP, Prestigiacomo AF & Stamey TA 1995 Ultrasensitive assay of prostate specific antigen used for early detection of prostate cancer relapse and estimation of tumor doubling time after radical prostatectomy. Clinical Chemistry 41 430-434.
142. Yu H, Diamandis EP, Wong PY, Nam R & Trachtenberg J 1997 Detection of prostate cancer relapse with prostate specific antigen monitoring at levels of 0.0001 to 0.1 μg/1. Journal of Urology 157 913-918.
143. Yuan JJ, Coplen DE, Petros JA, Figenshau RS, Ratliff TL, Smith D & Catalona WJ 1992 Effects of rectal examination, prostatic massage, ultrasonography and needle biopsy on serum prostate-specific antigen levels. Journal of Urology 147 810-814.
144. Zagars G & Pollock A 1995 Radiation therapy for T1 and T2 prostate cancer: prostate specific antigen and disease outcome. Urology 45 476-483.
145. Zlotta AR, Djavan B, Marberger M & Schulman CC 1997 Prostate specific antigen density of the transition zone: a new effective parameter for prostate cancer prediction. Journal of Urology 157 1315-1321.